决定异体 CAR T 细胞排斥与扩增的细胞和分子机制
Cellular and molecular mechanisms determining allogeneic CAR T cell rejection and expansion.
我们评估了11例接受单一批次cemacabtagene ansegedleucel(cema-cel)治疗的大B细胞淋巴瘤患者,cemacabtagene ansegedleucel是一种异体抗CD19 CAR T产品。
英文原题:RETRACTED: Enhanced AC133-specific CAR T cell therapy induces durable remissions in mice with metastatic small cell lung cancer.
本文已被撤稿:请参阅 Elsevier 关于文章撤稿的政策(https://www.elsevier.com/about/our-business/policies/article-withdrawal)。
本文已撤稿:请参阅Elsevier《文章撤回政策》(https://www.elsevier.com/about/our-business/policies/article-withdrawal)。应主编要求,本文被撤回。上述文章发表后,编辑获知所有图片均误用了错误版本。编辑认为,鉴于图像和文章需要进行大幅修改,修正勘误将导致读者产生歧义,因此稿件以当前形式或通过勘误均不再可接受。故决定从《Cancer Letters》撤回该稿;待按正确版本修改后,可重新投稿并在同行评审后重新发表。
This article has been retracted: please see Elsevier Policy on Article Withdrawal (https://www.elsevier.com/about/our-business/policies/article-withdrawal). This article has been retracted at the request of the Editor-in-Chief. Following the publication of the above article, the Editor was notified that an error occurred in which all images were published with incorrect versions. The Editor has taken the decision that the manuscript is no longer acceptable in its current form, nor with a corrigendum, as the extensive changes to the figures and publication would lead to ambiguity for our readers. We have therefore made the decision to retract this manuscript from Cancer Letters with the possibility of resubmission and republication of the manuscript in its corrected form after peer review.
MEMBER ACCOUNT
登录成功会直接打开下一页。